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1. INTRODUCTION {#dom13681-sec-0005}
===============

The global burden of type 2 diabetes (T2DM) is increasing, particularly in Asia.[1](#dom13681-bib-0001){ref-type="ref"} Following current trends, diabetes could affect 693 million adults worldwide by the year 2045.[1](#dom13681-bib-0001){ref-type="ref"} In China, 11.6% (113.9 million) of the adult population are estimated to have diabetes, with T2DM accounting for the vast majority of cases.[2](#dom13681-bib-0002){ref-type="ref"} Several factors are probably contributing to the increased prevalence in the Asian population including urbanization and accompanying obesity, along with increasing age.[3](#dom13681-bib-0003){ref-type="ref"}

Metformin is the standard first‐line pharmacological agent for the majority of patients with T2DM.[4](#dom13681-bib-0004){ref-type="ref"} However, because of the progressive nature of T2DM, over time many patients fail to maintain adequate glycaemic control on metformin monotherapy, and require additional antihyperglycaemic therapy. Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors reduce renal glucose reabsorption, leading to favourable effects on glycaemic control, blood pressure (BP) and body weight control.[5](#dom13681-bib-0005){ref-type="ref"}, [6](#dom13681-bib-0006){ref-type="ref"}, [7](#dom13681-bib-0007){ref-type="ref"}, [8](#dom13681-bib-0008){ref-type="ref"} The insulin‐independent mechanism enables their use across the natural progression of T2DM.

Ertugliflozin, a selective inhibitor of SGLT2,[9](#dom13681-bib-0009){ref-type="ref"}, [10](#dom13681-bib-0010){ref-type="ref"} is currently approved in the United States,[11](#dom13681-bib-0011){ref-type="ref"} the European Union (EU)[12](#dom13681-bib-0012){ref-type="ref"} and other regions including Canada[13](#dom13681-bib-0013){ref-type="ref"} and Australia,[14](#dom13681-bib-0014){ref-type="ref"} as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM. Phase III trials have shown that ertugliflozin alone or in combination with metformin or metformin and sitagliptin significantly reduces HbA1c, fasting plasma glucose (FPG), body weight and BP.[15](#dom13681-bib-0015){ref-type="ref"}, [16](#dom13681-bib-0016){ref-type="ref"}, [17](#dom13681-bib-0017){ref-type="ref"}, [18](#dom13681-bib-0018){ref-type="ref"}, [19](#dom13681-bib-0019){ref-type="ref"}, [20](#dom13681-bib-0020){ref-type="ref"}, [21](#dom13681-bib-0021){ref-type="ref"}, [22](#dom13681-bib-0022){ref-type="ref"} This phase III study assessed the efficacy, safety and tolerability of ertugliflozin relative to placebo in adult Asian patients with T2DM and included a prespecified analysis of the China subpopulation to support the registration of ertugliflozin in China.

2. METHODS {#dom13681-sec-0006}
==========

This was a 26‐week, double‐blind, placebo‐controlled, multicentre, randomized, parallel‐group, phase III study in Asian patients with T2DM and inadequate glycaemic control on metformin monotherapy. The final protocol and informed consent documentation were reviewed and approved by the institutional review board or independent ethics committee at each investigational centre. The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and in compliance with all International Conference on Harmonisation Good Clinical Practice Guidelines. Written informed consent was obtained from all participants ([ClinicalTrials.gov](http://clinicaltrials.gov): NCT02630706).

2.1. Study design and treatment {#dom13681-sec-0007}
-------------------------------

The trial design is shown in Supporting Information Figure [S1](#dom13681-supitem-0001){ref-type="supplementary-material"}. The study included a screening period (during which, if needed, background diabetes medication was adjusted to achieve a minimum 8‐week metformin monotherapy stable dose \[≥1500 mg/d\]), followed by a 2‐week, single‐blind, placebo run‐in period prior to randomization, a 26‐week double‐blind, placebo‐controlled treatment period, and post‐treatment telephone contact 14 days after the last dose of blinded study medication. Participants were counselled on appropriate dietary and lifestyle guidelines for T2DM. On day 1 (randomization), each participant was assigned (1:1:1) to oral, once‐daily ertugliflozin 5 mg, 15 mg or placebo using a computer‐generated randomization code based on the method of random permuted blocks. Randomization was stratified by "Mainland China" and "Other". Participants received glycaemic rescue therapy with open‐label glimepiride and dosed according to physician judgement, if they met specific, progressively more stringent, glycaemic thresholds. Participants who received glycaemic rescue therapy remained in the study and continued to receive background metformin and blinded study medication, ertugliflozin or matching placebo.

2.2. Participant population {#dom13681-sec-0008}
---------------------------

The population comprised Asian men and women aged ≥18 years with T2DM (diagnosed in accordance with American Diabetes Association guidelines)[4](#dom13681-bib-0004){ref-type="ref"} inadequately controlled \[HbA1c, 7.0‐10.5% (53‐91 mmol/mol) inclusive\] with metformin monotherapy and with a body mass index (BMI) ≥18.0 kg/m^2^. Participants who had received dual antihyperglycaemic agent (AHA) therapy, metformin monotherapy \<1500 or ≥1500 mg/d for \<8 weeks were required to adjust their background AHA therapy so that, at a second screening visit, they had received metformin monotherapy at ≥1500 mg/d for ≥8 weeks. To be eligible for study inclusion, these participants underwent a repeat HbA1c measurement for confirmation of HbA1c 7.0 to 10.5% (53‐91 mmol/mol) inclusive. Participants were required to be receiving stable doses of BP and/or lipid‐altering medications for ≥4 weeks prior to randomization.

Key exclusion criteria included type 1 diabetes mellitus, history of ketoacidosis, estimated glomerular filtration rate (eGFR) \<55 mL/min/1.73 m^2^ according to the 4‐variable Modification of Diet in Renal Disease equation at screening, and \<80% compliance (based on pill count) with the placebo run‐in medication. Use of AHAs (other than those approved by the study protocol) was prohibited for the duration of the trial. Participants who had undergone bariatric surgery were also ineligible.

2.3. Efficacy assessments {#dom13681-sec-0009}
-------------------------

The primary efficacy endpoint was the change from baseline in HbA1c at week 26. Secondary efficacy endpoints included change from baseline at week 26 in FPG, body weight, systolic BP and diastolic BP, and the proportion of patients with HbA1c \<7% (53 mmol/mol) for the secondary hypotheses. Other assessments included the proportion of patients with HbA1c \<6.5% (48 mmol/mol) and the proportion of patients requiring glycaemic rescue therapy. Hypotheses for the primary and secondary endpoints were assessed in the overall study population. Hypotheses for the primary endpoint and the secondary endpoints of FPG and body weight were also tested in patients from mainland China (China subpopulation). Laboratory assessments were performed at a central laboratory. Body weight was measured in duplicate using a standardized digital scale. Sitting BP was measured in triplicate using an automated oscillometric device.

2.4. Safety assessments {#dom13681-sec-0010}
-----------------------

Safety assessments included adverse events (AEs), drug‐related AEs, serious AEs (SAEs), deaths, discontinuations because of AEs, eGFR change from baseline over time, vital signs and laboratory evaluations. Genital mycotic infection (GMI) by gender, urinary tract infection (UTI), symptomatic hypoglycaemia and hypovolaemia were prespecified AEs of special interest (Tier 1 AEs). Clinical adjudication committees, comprising external panels of independent physicians blinded to patient treatment assignments, evaluated cardiovascular events, fractures, pancreatitis and renal and hepatic events. Potential cases of ketoacidosis were reviewed by an internal blinded case review committee, independent from the study team, to assess whether the cases met a prespecified definition of ketoacidosis. An external data monitoring committee monitored unblinded, interim data from this study and other phase III studies in the ertugliflozin development programme. There was no interim analysis of efficacy for this study. Safety data were provided to the external data monitoring committee for periodic reviews of safety.

2.5. Statistical analysis {#dom13681-sec-0011}
-------------------------

The sample size was based on the reduction in HbA1c from baseline at week 26, from the patients enrolled from mainland China. Assuming a standard deviation (SD) of 1.0%, a sample size of 105 patients from mainland China per group (315 in total) provided \~95% power to detect a difference in HbA1c change from baseline of 0.5% between each ertugliflozin dose and placebo (and \~90% power for detecting this difference for both doses vs. placebo) using a two‐sided 0.05 alpha level test. Assuming a dropout rate of 20% at week 26 (i.e. either patients who discontinued from the study, discontinued study medication or took rescue medication and were censored), \~396 patients from mainland China (132 per group) were to be randomized. In addition, this study was to include \~99 patients from at least two other Asian countries. The total sample size planned for this study was \~495 randomized patients.

### 2.5.1. Analysis of efficacy endpoints {#dom13681-sec-0012}

Efficacy analyses comprised all randomized patients who received ≥1 dose of study medication. The China subpopulation was assessed in parallel to the overall population. For the China subpopulation, efficacy analyses consisted of patients who were in the full analysis set for overall study population and enrolled from mainland China. For endpoints that used a longitudinal data analysis (LDA) model, at least one measurement (baseline or postbaseline) was required.

Efficacy endpoints were summarized using the excluding glycaemic rescue approach, i.e. efficacy data obtained after the initiation of glycaemic rescue therapy were censored (treated as missing). A sequential testing approach was used to assess the primary and secondary efficacy hypotheses to control the type 1 error rate at the 0.05 level within each population (overall study population and China subpopulation). For each endpoint, the 15‐mg dose was tested versus placebo first, followed by the 5‐mg dose versus placebo. Each test was performed at the 0.05 level, and testing continued until the first *P*‐value was ≥0.05. This testing strategy was used in the overall population for HbA1c, FPG, body weight, HbA1c \<7.0% (53 mmol/mol), systolic BP and diastolic BP, and within the China subpopulation for the HbA1c, FPG and body weight endpoints. If any prior *P*‐value did not meet the \<0.05 criterion, *P*‐values for subsequent comparisons were provided for reference only and were considered nominal. In the China subpopulation, the 95% CI and nominal *P*‐values were provided for secondary endpoints without statistical hypothesis testing \[HbA1c \<7.0% (53 mmol/mol), systolic BP and diastolic BP\]. Changes from baseline at week 26 were assessed using an LDA model for the ertugliflozin groups that included terms for country (binary, 'Mainland China vs. Other', applicable only for the analyses of the overall study population), treatment (categorical), visit (categorical), treatment by visit interaction, AHA status at study entry (binary) and baseline eGFR (continuous) with baseline constrained to be the same. A logistic regression analysis was used to evaluate the proportion of patients with HbA1c \<7.0% (53 mmol/mol) and HbA1c \<6.5% (48 mmol/mol) at week 26 using the excluding glycaemic rescue approach. Missing data at week 26 were imputed via a multiple imputation procedure based on the LDA model. The proportion of patients requiring glycaemic rescue therapy up to week 26 was analyzed by treatment using the Miettinen and Nurminen method (stratified by country for the overall population) based on all patients treated.[23](#dom13681-bib-0023){ref-type="ref"}

### 2.5.2. Analysis of safety endpoints {#dom13681-sec-0013}

Safety analyses included all randomized patients who took ≥1 dose of study medication. With the exception of hypoglycaemia, safety analyses were conducted including using the glycaemic rescue approach. Safety endpoints of a priori interest (Tier 1 AEs of GMI by gender, UTI, symptomatic hypoglycaemia and hypovolaemia) were assessed using 95% confidence intervals (CI), and *P*‐values provided without multiplicity control using the Miettinen and Nurminen method.[23](#dom13681-bib-0023){ref-type="ref"}

3. RESULTS {#dom13681-sec-0014}
==========

3.1. Patient disposition and baseline characteristics {#dom13681-sec-0015}
-----------------------------------------------------

In total, 506 patients were randomized (Supporting Information Table [S1](#dom13681-supitem-0001){ref-type="supplementary-material"}), including 406 patients in mainland China. Overall, 465 (92%) patients completed the study medication. The proportion of patients who discontinued the study medication was higher in the placebo group compared with ertugliflozin (Supporting Information Table [S1](#dom13681-supitem-0001){ref-type="supplementary-material"}). Patient withdrawal was the most common reason for discontinuation of study medication for both ertugliflozin and placebo. Twenty‐six of the 41 (8.1%) patients who discontinued study medication, discontinued from the study (placebo: 10; ertugliflozin 5 mg: 7; ertugliflozin 15 mg: 9).

Baseline demographics and characteristics were similar across treatment groups (Table [1](#dom13681-tbl-0001){ref-type="table"}). Overall, 55.5% of patients were male with a mean age (SD) of 56.5 (9.1) years and a mean duration of T2DM of 7.0 (5.1) years. The majority of patients were enrolled in mainland China (80.2%). Baseline HbA1c, FPG and eGFR values were similar across treatment groups. At baseline, mean HbA1c (SD) was 8.1% (0.9) \[65.2 (10.1) mmol/mol\] and eGFR was 99.3 mL/min/1.73 m^2^. The mean duration of T2DM and the proportion of patients on background AHA therapy at screening were similar across the treatment groups. The median metformin dose at randomization was 1500 mg/day for the ertugliflozin and placebo groups with 69.4% of patients on 1500 mg/day at randomization. The baseline demographics and characteristics of patients in the China subpopulation were similar to the overall population and were similar across treatment groups (Supporting Information Table [S2](#dom13681-supitem-0001){ref-type="supplementary-material"}).

###### 

Baseline demographics and characteristics of overall population

                                                                                      Placebo (n = 167)   Ertugliflozin 5 mg (n = 170)   Ertugliflozin 15 mg (n = 169)   Total (N = 506)
  ----------------------------------------------------------------------------------- ------------------- ------------------------------ ------------------------------- -----------------
  Male, n (%)                                                                         88 (52.7)           95 (55.9)                      98 (58.0)                       281 (55.5)
  Age, y                                                                              56.9 (9.0)          56.1 (9.0)                     56.3 (9.3)                      56.5 (9.1)
  Age ≥65 y, n (%)                                                                    35 (21.0)           28 (16.5)                      34 (20.1)                       97 (19.2)
  Duration of T2DM, y                                                                 6.4 (5.1)           7.0 (5.0)                      7.5 (5.1)                       7.0 (5.1)
  Distribution of metformin dose at randomization, n (%)                                                                                                                 
  1500                                                                                113 (67.7)          118 (69.4)                     120 (71.0)                      351 (69.4)
  \>1500 and \<2000                                                                   8 (4.8)             10 (5.9)                       8 (4.7)                         26 (5.1)
  2000                                                                                43 (25.7)           35 (20.6)                      40 (23.7)                       118 (23.3)
  \>2000 and \<3000                                                                   3 (1.8)             4 (2.4)                        0 (0.0)                         7 (1.4)
  3000                                                                                0 (0.0)             3 (1.8)                        1 (0.6)                         4 (0.8)
  Background AHA therapy at screening,[a](#dom13681-note-0004){ref-type="fn"} n (%)                                                                                      
  Alpha glucosidase inhibitors                                                        8 (4.8)             11 (6.5)                       4 (2.4)                         23 (4.5)
  Biguanides                                                                          167 (100.0)         170 (100.0)                    169 (100.0)                     506 (100.0)
  DPP‐4 inhibitors                                                                    1 (0.6)             3 (1.8)                        5 (3.0)                         9 (1.8)
  Meglitinide                                                                         7 (4.2)             11 (6.5)                       5 (3.0)                         23 (4.5)
  Sulphonylurea                                                                       30 (18.0)           34 (20.0)                      34 (20.1)                       98 (19.4)
  Number of agents                                                                                                                                                       
  1                                                                                   121 (72.5)          111 (65.3)                     121 (71.6)                      353 (69.8)
  2                                                                                   46 (27.5)           59 (34.7)                      48 (28.4)                       153 (30.2)
  Country, n (%)                                                                                                                                                         
  China                                                                               135 (80.8)          136 (80.0)                     135 (79.9)                      406 (80.2)
  Other                                                                               32 (19.2)           34 (20.0)                      34 (20.1)                       100 (19.8)
  Hong Kong                                                                           7 (4.2)             10 (5.9)                       10 (5.9)                        27 (5.3)
  Korea, Republic of                                                                  9 (5.4)             13 (7.6)                       10 (5.9)                        32 (6.3)
  Philippines                                                                         8 (4.8)             7 (4.1)                        8 (4.7)                         23 (4.5)
  Taiwan                                                                              8 (4.8)             4 (2.4)                        6 (3.6)                         18 (3.6)
  Body weight, kg                                                                     70.1 (12.4)         71.4 (11.1)                    69.5 (10.9)                     70.3 (11.5)
  BMI, kg/m^2^                                                                        26.1 (3.4)          26.0 (2.8)                     25.7 (3.2)                      26.0 (3.2)
  Baseline HbA1c, %                                                                   8.1 (1.0)           8.1 (0.9)                      8.1 (0.9)                       8.1 (0.9)
  Baseline FPG, mg/dL                                                                 165.8 (37.6)        170.1 (36.0)                   167.3 (41.1)                    167.8 (38.3)
  Baseline eGFR, mL/min/1.73 m^2^                                                     99.9 (20.2)         97.9 (19.2)                    100.2 (19.8)                    99.3 (19.7)
  30 to \<60, n (%)                                                                   3 (1.8)             2 (1.2)                        3 (1.8)                         8 (1.6)
  60 to \<90, n (%)                                                                   48 (28.7)           56 (32.9)                      50 (29.6)                       154 (30.4)
  ≥90, n (%)                                                                          116 (69.5)          112 (65.9)                     116 (68.6)                      344 (68.0)

Abbreviations: AHA, antihyperglycaemic agents; BMI, body mass index; DPP‐4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; SD, standard deviation; T2DM, type 2 diabetes mellitus.

Data presented are mean (SD) unless otherwise stated.

Combination blood glucose‐lowering agents were counted twice, under each component of the combination.

3.2. Efficacy {#dom13681-sec-0016}
-------------

### 3.2.1. Overall population {#dom13681-sec-0017}

The placebo‐adjusted, least squares (LS) mean reduction (95% CI) from baseline in HbA1c at week 26 was −0.8% (−1.0, −0.6) with ertugliflozin 5 mg and −0.7% (−0.9, −0.5) with ertugliflozin 15 mg (*P* \< 0.001 for both comparisons with placebo; Table [2](#dom13681-tbl-0002){ref-type="table"}, Figures [1](#dom13681-fig-0001){ref-type="fig"} and [2](#dom13681-fig-0002){ref-type="fig"}A). More patients who received ertugliflozin 5 mg (38.2%) and 15 mg (40.8%) compared with placebo (16.2%) had HbA1c \<7.0% (53 mmol/mol) at week 26 (Figure [2](#dom13681-fig-0002){ref-type="fig"}B). The model‐based odds of having an HbA1c \<7.0% (53 mmol/mol) at week 26 were significantly greater with ertugliflozin relative to placebo (*P* \< 0.001 for both comparisons). More patients who received ertugliflozin 5 mg (14.7%) and 15 mg (15.4%) compared with placebo (2.4%) had HbA1c \<6.5% (48 mmol/mol) at week 26. The model‐based odds of having an HbA1c \<6.5% (48 mmol/mol) at week 26 were greater with ertugliflozin compared with placebo (nominal *P* = 0.001 and nominal *P* \< 0.001 for ertugliflozin 15 mg and ertugliflozin 5 mg, respectively). Both ertugliflozin doses provided significantly greater reductions from baseline in FPG (Figure [2](#dom13681-fig-0002){ref-type="fig"}C), body weight (Figure [2](#dom13681-fig-0002){ref-type="fig"}D) and systolic BP (Figure [2](#dom13681-fig-0002){ref-type="fig"}E) compared with placebo (*P* \< 0.001 for both comparisons). The LS mean reductions from baseline at week 26 in diastolic BP were greater with ertugliflozin compared with placebo, but the differences were not statistically significant (Figure [2](#dom13681-fig-0002){ref-type="fig"}F). By week 26, a larger proportion of patients in the placebo group (9.6%) had received glycaemic rescue therapy compared with the ertugliflozin groups (both \<1.2%).

###### 

Change from baseline in HbA1c at week 26 for overall population

  Treatment                                 Baseline                                                                 Week 26     Change from baseline at week 26                                  
  ----------------------------------------- ------------------------------------------------------------------------ ----------- --------------------------------- ----------- ----- ------------ -------------------
  Placebo                                   166                                                                      8.1 (1.0)   132                               7.7 (1.0)   167   −0.2 (0.8)   −0.2 (−0.3, −0.1)
  Ertugliflozin 5 mg                        169                                                                      8.1 (0.9)   155                               7.1 (0.8)   170   −1.0 (0.9)   −1.0 (−1.1, −0.9)
  Ertugliflozin 15 mg                       169                                                                      8.1 (0.9)   153                               7.2 (0.8)   169   −0.9 (0.8)   −0.9 (−1.0, −0.8)
  Pairwise comparison                       Difference in LS means (95% CI)[a](#dom13681-note-0007){ref-type="fn"}   *P*‐value                                                                    
  Week 26 ertugliflozin 5 mg vs. placebo    −0.8 (−1.0, −0.6)                                                        \<0.001                                                                      
  Week 26 ertugliflozin 15 mg vs. placebo   −0.7 (−0.9, −0.5)                                                        \<0.001                                                                      

Abbreviations: AHA, antihyperglycaemic agents; CI, confidence interval; cLDA, constrained longitudinal data analysis; eGFR, estimated glomerular filtration rate; LS, least squares; SD, standard deviation.

For baseline and week 26, n was the number of patients with non‐missing assessments at the specific timepoint; for change from baseline at week 26, n was the number of randomized patients who took at least one dose of study medication and had at least one assessment at or after baseline. The mean and SD for the change from baseline are based on non‐missing values.

Based on a cLDA model with fixed effects for treatment, time, prior antihyperglycaemic medication (metformin monotherapy or metformin plus another AHA), country (China or other), baseline eGFR (continuous), and the interaction of time by treatment. Time was treated as a categorical variable.

![Least squares mean change from baseline in HbA1c over time for overall population. Based on cLDA model with fixed effects for treatment, time, antihyperglycaemic medication status at screening, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable. cLDA, constrained longitudinal data analysis; eGFR, estimated glomerular filtration rate; LS, least squares; SE, standard error](DOM-21-1474-g001){#dom13681-fig-0001}

![Efficacy outcomes in overall population: A, least squares mean change from baseline in HbA1c at week 26; B, proportion of patients with HbA1c \<7% at week 26; C, LS mean change from baseline in FPG at week 26; D, LS mean change from baseline in body weight at week 26; E, LS mean change from baseline in systolic BP at week 26; F, LS mean change from baseline in diastolic BP at week 26; BP, blood pressure; CI, confidence interval; FPG, fasting plasma glucose; LS, least squares](DOM-21-1474-g002){#dom13681-fig-0002}

### 3.2.2. China subpopulation {#dom13681-sec-0018}

The placebo‐adjusted, LS mean reduction (95% CI) from baseline in HbA1c at week 26 was −0.8% (−1.0, −0.6) with ertugliflozin 5 mg and −0.7% (−0.9, −0.5) with ertugliflozin 15 mg (*P* \< 0.001 for both comparisons with placebo; Supporting Information Table [S3](#dom13681-supitem-0001){ref-type="supplementary-material"}, Figures [S2 and S3A](#dom13681-supitem-0001){ref-type="supplementary-material"}). More patients who received ertugliflozin 5 mg (35.3%) and 15 mg (42.2%) compared with placebo (18.5%) had HbA1c \<7.0% (53 mmol/mol) at week 26 (Supporting Information Figure [S3B](#dom13681-supitem-0001){ref-type="supplementary-material"}). The model‐based odds of having an HbA1c \<7.0% (53 mmol/mol) at week 26 were greater with ertugliflozin relative to placebo (nominal *P* \< 0.001 for both comparisons). More patients who received ertugliflozin 5 mg (14.7%) and 15 mg (17.0%) compared with placebo (3.0%) had HbA1c \<6.5% (48 mmol/mol) at week 26. The model‐based odds of having an HbA1c \<6.5% (48 mmol/mol) at week 26 were greater with ertugliflozin compared with placebo (nominal *P* \< 0.001 for both comparisons). Both ertugliflozin doses provided significantly greater reductions from baseline in FPG and body weight compared with placebo (Supporting Information Figure [S3](#dom13681-supitem-0001){ref-type="supplementary-material"}C, D). The LS mean reductions from baseline at week 26 in systolic BP and diastolic BP were greater with ertugliflozin compared with placebo (Supporting Information Figure [S3](#dom13681-supitem-0001){ref-type="supplementary-material"}E, F).

3.3. Safety {#dom13681-sec-0019}
-----------

### 3.3.1. Overall AE summary {#dom13681-sec-0020}

The overall incidence of AEs and drug‐related AEs was similar across the treatment groups (Table [3](#dom13681-tbl-0003){ref-type="table"}). The incidence of SAEs was higher with ertugliflozin than with placebo (Table [3](#dom13681-tbl-0003){ref-type="table"}). No SAEs were considered drug‐related with ertugliflozin. One SAE in the placebo group was reported as drug‐related by the investigator. The incidence of AEs resulting in discontinuation from study medication was low (\<2% of patients in any group). No deaths occurred between the first dose of treatment and 14 days after the final dose of treatment in the study; one death occurred in the China subpopulation in the postrandomization follow‐up period (i.e. \>14 days after the last dose of study medication). The patient, treated with ertugliflozin 15 mg, was diagnosed with metastatic lung cancer 20 days after the last dose of study medication and died 71 days after the last dose of study medication. There were no confirmed cases of diabetic ketoacidosis in the study population. The incidence of AEs, drug‐related AEs, SAEs and discontinuations across treatment groups was similar in the China subpopulation (Supporting Information Table [S4](#dom13681-supitem-0001){ref-type="supplementary-material"}).

###### 

Summary of adverse events for overall population

+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Event, n (%)                                                       | Placebo   | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|                                                                    |           |                    |                     |
|                                                                    | (n = 167) | (n = 170)          | (n = 169)           |
+:===================================================================+:==========+:===================+:====================+
| ≥1 AE                                                              |           |                    |                     |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Overall                                                            | 99 (59.3) | 96 (56.5)          | 90 (53.3)           |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Drug‐related[a](#dom13681-note-0010){ref-type="fn"}                | 23 (13.8) | 29 (17.1)          | 24 (14.2)           |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| ≥1 SAE                                                             |           |                    |                     |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Overall                                                            | 2 (1.2)   | 9 (5.3)            | 10 (5.9)            |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Drug‐related[a](#dom13681-note-0010){ref-type="fn"}                | 1 (0.6)   | 0                  | 0                   |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Discontinuations                                                   |           |                    |                     |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Because of AE                                                      | 3 (1.8)   | 2 (1.2)            | 1 (0.6)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Because of drug‐related[a](#dom13681-note-0010){ref-type="fn"} AE  | 1 (0.6)   | 1 (0.6)            | 0                   |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Because of SAE                                                     | 0         | 1 (0.6)            | 1 (0.6)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Because of drug‐related[a](#dom13681-note-0010){ref-type="fn"} SAE | 0         | 0                  | 0                   |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Deaths[b](#dom13681-note-0011){ref-type="fn"}                      | 0         | 0                  | 0                   |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Tier 1AEs                                                          |           |                    |                     |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| GMI (women)                                                        | 1 (1.3)   | 2 (2.7)            | 1 (1.4)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| GMI (men)                                                          | 1 (1.1)   | 2 (2.1)            | 2 (2.0)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| UTI                                                                | 4 (2.4)   | 3 (1.8)            | 2 (1.2)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Symptomatic hypoglycaemia                                          | 1 (0.6)   | 4 (2.4)            | 8 (4.7)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Hypovolaemia                                                       | 1 (0.6)   | 0                  | 1 (0.6)             |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Other selected AEs                                                 |           |                    |                     |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+
| Documented hypoglycaemia[c](#dom13681-note-0012){ref-type="fn"}    | 5 (3.0)   | 11 (6.5)           | 14 (8.3)            |
+--------------------------------------------------------------------+-----------+--------------------+---------------------+

Abbreviations: AE, adverse event; GMI, genital mycotic infection; SAE, serious adverse event; UTI, urinary tract infection.

For all AEs, this table contains events that occurred between the first dose of treatment and 14 d after the final dose of treatment.

Assessed as related to the study drug by the investigator.

No deaths occurred between the first dose of treatment and 14 d after the final dose of treatment in the study; there was one death in the China subpopulation in the all postrandomization follow‐up period (\>14 d after the last dose of study medication). The patient, treated with ertugliflozin 15 mg, was diagnosed with metastatic lung cancer 20 d after the last dose of study medication and died 71 d after the last dose of study medication.

Episodes with a glucose level ≤70 mg/dL (≤3.9 mmol/L) with or without symptoms.

### 3.3.2. Tier 1 AEs/AEs of special interest {#dom13681-sec-0021}

The incidence of GMIs was low and similar across treatment groups (Table [3](#dom13681-tbl-0003){ref-type="table"}). No patients experienced a complicated genital infection and no GMI AEs led to discontinuation of study medication. The incidence of UTI AEs was similar across groups (Table [3](#dom13681-tbl-0003){ref-type="table"}). All UTI AEs were non‐serious. No patients experienced a complicated UTI and no UTI AEs led to discontinuation of study medication. The incidence of symptomatic hypoglycaemia was low across the groups, but significantly higher with ertugliflozin 15 mg compared with placebo in the overall population (4.7% vs. 0.6%, *P* = 0.019). The incidence of documented hypoglycaemia \[episodes with a glucose level ≤70 mg/dL (≤3.9 mmol/L) with or without symptoms\] was higher with ertugliflozin compared with placebo (Table [3](#dom13681-tbl-0003){ref-type="table"}). There were no cases of severe hypoglycaemia. The incidence of hypovolaemia was low across treatment groups. The incidence of Tier 1 AEs across treatment groups for the China subpopulation was generally similar to the overall subpopulation (Supporting Information Table [S4](#dom13681-supitem-0001){ref-type="supplementary-material"}).

### 3.3.3. Laboratory parameters {#dom13681-sec-0022}

Changes from baseline through week 26 in relevant laboratory parameters are shown in Supporting Information Table [S5](#dom13681-supitem-0001){ref-type="supplementary-material"}.

4. DISCUSSION {#dom13681-sec-0023}
=============

Ertugliflozin 5 and 15 mg once daily in addition to metformin monotherapy over 26 weeks significantly improved glycaemic control and reduced body weight and systolic BP in Asian patients with T2DM. Treatment with ertugliflozin also resulted in significant improvements relative to placebo in other glycaemic measures, including FPG, and in the proportion of patients with HbA1c \<7% (53 mmol/mol).

Both the 5 mg and 15 mg doses of ertugliflozin were evaluated in the global phase III programme.[15](#dom13681-bib-0015){ref-type="ref"}, [16](#dom13681-bib-0016){ref-type="ref"}, [18](#dom13681-bib-0018){ref-type="ref"}, [19](#dom13681-bib-0019){ref-type="ref"}, [20](#dom13681-bib-0020){ref-type="ref"}, [21](#dom13681-bib-0021){ref-type="ref"}, [22](#dom13681-bib-0022){ref-type="ref"}, [24](#dom13681-bib-0024){ref-type="ref"} Ertugliflozin 5 mg and 15 mg provide effects on urinary glucose excretion and HbA1c that are \>80% and \>90% of the maximum response for these endpoints, respectively.[25](#dom13681-bib-0025){ref-type="ref"} In a pooled analysis of three placebo‐controlled studies, ertugliflozin 15 mg produced incremental HbA1c lowering of 0.15% relative to ertugliflozin 5 mg.[26](#dom13681-bib-0026){ref-type="ref"} One of the studies included in this pooled analysis evaluated ertugliflozin added to metformin monotherapy, and showed placebo‐adjusted changes in HbA1c of −0.70% and −0.88% for ertugliflozin 5 mg and 15 mg, respectively.[15](#dom13681-bib-0015){ref-type="ref"} On the basis of the results from the phase III programme, the approved ertugliflozin labelling in the United States and EU recommends a starting dose of 5 mg, increasing to 15 mg if therapy is well‐tolerated and if additional glycaemic control is needed.[11](#dom13681-bib-0011){ref-type="ref"}, [14](#dom13681-bib-0014){ref-type="ref"}

In the current study, the efficacy on HbA1c was similar between ertugliflozin 5 mg and 15 mg but the estimated mean was \~0.1% greater for ertugliflozin 5 mg relative to ertugliflozin 15 mg in both the overall population and China subpopulation. A pooled analysis of three other placebo‐controlled studies (N = 1544) assessing the efficacy and safety of ertugliflozin by race showed no notable differences in HbA1c, body weight and SBP reductions between racial subgroups.[27](#dom13681-bib-0027){ref-type="ref"} In the analysis, the placebo‐adjusted LS mean change (95% CI) in HbA1c at week 26 was −0.8% (−1.1, −0.5) with ertugliflozin 5 mg and −1.0% (−1.3, −0.8) with ertugliflozin 15 mg for Asian patients (n = 221). The results from the current study in Asian patients may therefore reflect a stochastic finding given that both ertugliflozin 5 mg and 15 mg are near the top end of the dose--response curve.

In addition, in this current study of Asian patients, both the point estimates of the reduction in body weight and the proportion of patients with HbA1c \<7.0% (53 mmol/mol) at week 26 were greater for ertugliflozin 15 mg relative to 5 mg in both the overall population and the China subpopulation.

The baseline patient characteristics in the current study are typical of an Asian population, with mean weight and BMI lower than in VERTIS MET, a previous study of ertugliflozin in a Western population.[15](#dom13681-bib-0015){ref-type="ref"} Despite this lower mean baseline weight, ertugliflozin resulted in significantly greater reductions in body weight with a magnitude similar to that observed in the overall phase III programme, and significantly greater reductions from baseline in systolic BP at week 26 relative to placebo, showing that ertugliflozin reduces body weight in populations with lower mean BMI as well as in populations with higher BMIs.[15](#dom13681-bib-0015){ref-type="ref"}

Ertugliflozin was generally well‐tolerated in the overall population and China subpopulation. The incidence of UTI, GMIs and hypovolaemia‐related AEs was low and similar across treatment groups in both the overall population and China subpopulation. An increased incidence of GMIs is often observed with SGLT2 inhibitors because of the associated glucosuria. In a pooled analysis of three placebo‐controlled studies, ertugliflozin increased the incidence of GMIs.[26](#dom13681-bib-0026){ref-type="ref"} In the current study, the similar incidence of GMI with ertugliflozin and placebo could reflect a chance finding given the sample size in the study and prior available data with ertugliflozin and other SGLT2 inhibitors. In the overall population, the incidence of symptomatic hypoglycaemia and episodes of documented hypoglycaemia were higher with ertugliflozin 15 mg compared with placebo. However, the number of patients with symptomatic hypoglycaemia was low (ertugliflozin 5 mg: 4; ertugliflozin 15 mg: 8). Therefore, these differences were not deemed to be clinically meaningful. Hypoglycaemia results for the China subpopulation were generally similar to the overall population.

The majority of patients (80%) included in this study were residents of mainland China. Efficacy and safety results in the China subpopulation were similar to the overall study population. In the China subpopulation, ertugliflozin added once daily to metformin monotherapy over 26 weeks significantly improved glycaemic control and reduced body weight. Clinically meaningful improvements were observed in other endpoints including the proportion of patients with HbA1c \<7% (53 mmol/mol) and reductions in systolic BP and diastolic BP.

In conclusion, in Asian patients with T2DM and inadequate glycaemic control on metformin monotherapy, the addition of ertugliflozin (15 mg and 5 mg) improves glycaemic control and reduces body weight and BP over 26 weeks. Ertugliflozin treatment was associated with a significantly greater proportion of patients achieving HbA1c \<7% (53 mmol/mol) relative to placebo. Ertugliflozin was generally well‐tolerated. Efficacy and safety results in the China subpopulation were consistent with the overall population.
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Upon request, and subject to certain criteria, conditions and exceptions (see <https://www.pfizer.com/science/clinical-trials/trial-data-and-results> <https://www.pfizer.com/science/clinical-trials/trial-data-and-results> [www.pfizer.com/science/clinical-trials/trial-data-and-results](https://www.pfizer.com/science/clinical-trials/trial-data-and-results) for more information), Pfizer will provide access to individual de‐identified participant data from Pfizer‐sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (a) for indications that have been approved in the United States and/or EU or (b) in programs that have been terminated (i.e. development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de‐identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

[^1]: At time of study conduct.
